Amgen Competitive Intelligence & Landscape

Amgen is a worldwide pioneer in biotechnology that discovers, develops, manufactures, and delivers innovative medicines to combat some of the world's most challenging diseases [https://www.amgen.com/]. Established on April 8, 1980, as Applied Molecular Genetics Inc., the company helped establish the biotechnology industry from its U.S. headquarters in Thousand Oaks, California [https://www.amgen.com/about] [https://www.amgen.com/about/amgen-history]. Its mission is "To Serve Patients" [https://wwwext.amgen.com/pdfs/misc/Fact_Sheet_Amgen.pdf], striving to transform scientific and biotechnological promises into therapies that can restore health or save lives [https://www.amgen.com/about/mission-and-values].

Amgen specializes in creating biologic medicines using living cells, targeting serious illnesses where treatment options are often limited [https://amgen.com/]. The company's innovative medicines are available in approximately 100 countries and have reached millions of patients globally [https://www.amgen.com/products] [https://careers.amgen.com/en/About]. This extensive reach and dedication to patient care underscore its commitment to making a positive difference in the world [https://amgen.com/].

With approximately 31,500 employees worldwide, Amgen is led by Chairman and CEO Robert A. Bradway [https://wwwext.amgen.com/pdfs/misc/Fact_Sheet_Amgen.pdf] [https://www.amgen.com/about/leadership]. The company is publicly traded on NASDAQ under the ticker AMGN [https://wwwext.amgen.com/pdfs/misc/Fact_Sheet_Amgen.pdf]. Through a values-based approach deeply rooted in science and innovation, Amgen continues to transform new ideas and discoveries into essential medicines for patients with serious illnesses [https://investors.amgen.com/].

Amgen.com operates with a focus on biotechnology products, primarily pharmaceuticals. The company's approach to pricing prioritizes patient access and affordability, recognizing the essential role innovative medicines play in managing disease and containing long-term healthcare costs [amgen.com/responsibility/healthy-people/access-to-medicines/our-approach-to-pricing-access-and-affordability].

Amgen offers detailed pricing information for several of its key products, such as Aimovig® and Neulasta®, which can be found alongside their prescribing information on the company's product pages [amgen.com/products]. For specific product inquiries, adverse event reporting, or quality issues, customers can contact Amgen directly via phone or by visiting designated websites for healthcare professionals like amgenmedinfo.com [amgen.com/contact-us/product-inquiries].

In terms of financial assistance and patient programs, Amgen provides U.S. reimbursement support services, with dedicated phone numbers for specific medications like ACTIMMUNE® and XGEVA® [amgen.comext.amgen.com/responsibility/healthy-people/access-to-medicines/reimbursement-and-financial-assistance-programs]. Furthermore, Amgen launched the AmgenNow direct-to-patient program, which started with Repatha®, offering eligible patients a nearly 60% discount from the list price [amgen.com/newsroom/press-releases/2025/10/amgen-makes-repatha-available-through-amgennow-a-directtopatient-program-in-the-us]. This initiative aligns with Amgen's efforts to lower medicine costs for American patients and its commitment to innovation [investors.amgen.com/news-releases/news-release-details/amgen-takes-action-us-government-lower-cost-medicines-american/].

The company also develops branded biosimilars, which are integrated into their existing business capabilities, aiming to increase treatment options and potentially reduce costs for patients, payers, and health systems [amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/responsibility/amgen-2023-esg-report.pdf]. While supporting patient access, Amgen has expressed concerns about the “Inflation Reduction Act,” viewing its drug pricing provisions as a loss for patients and future innovation [amgen.com/newsroom/company-statements/statement-on-drug-pricing-provisions-included-in-inflation-reduction-act].

Amgen (amgen.com) is actively recruiting, with a strong emphasis on talent in Research and Development (R&D) and Digital Technology and Innovation. The company's careers portal highlights numerous opportunities, indicating a continuous need for skilled professionals in these critical areas [careers.amgen.com/en].

Recent job postings showcase a demand for specialized roles such as "Sr Data Scientist - PKDM-BA" in South San Francisco, California, posted on June 1, 2026, and a "Sr Engineer, PD Process Validation & Business Strategy" in Holly Springs, North Carolina [careers.amgen.com/en/job/south-san-francisco/sr-data-scientist-pkdm-ba/87/95877269376]. Additionally, Amgen is seeking a "Principal Scientist – Lead Discovery and Targeted Protein Degradation Biochemistry" in Thousand Oaks, California, posted on June 3, 2026 [careers.amgen.com/en/job/thousand-oaks/principal-scientist-lead-discovery-and-targeted-protein-degradation-biochemistry/87/95942076176]. These roles signal Amgen's strategic focus on advancing its scientific research and integrating cutting-edge digital solutions within its operations.

The emphasis on R&D reflects Amgen's core business as a biotechnology pioneer, covering all scientific aspects from discovering pathways to testing potential medicines. The push for Digital Technology and Innovation indicates a commitment to leveraging leading-edge technology and artificial intelligence to optimize research, development, and overall business processes [amgen.com]. This strategic hiring in both scientific and technological domains suggests an intent to drive innovation and maintain a competitive edge in the biopharmaceutical industry.

While specific layoff information is not detailed in the provided sources, Amgen's consistent recruitment across various scientific and technical fields, including opportunities for students and graduates, points towards a growth-oriented strategy and a healthy talent acquisition pipeline [careers.amgen.com/en/students-graduates]. The company also maintains a clear stance on ethical conduct during the hiring process, expecting honesty and integrity from all applicants [careers.amgen.com/en/search-jobs].

Amgen, a worldwide pioneer in biotechnology, has demonstrated robust financial performance. In 2024, the company achieved record total revenues of $33.4 billion, marking a 19% increase from the previous year, driven by a 23% volume growth as its medicines reached more patients globally [amgen.com/newsroom/press-releases/2025/02/amgen-reports-fourth-quarter-and-full-year-2024-financial-results]. Non-GAAP earnings per share rose by 6% to $19.84 [amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/investors/2024-annual-report-letter-and-10k.pdf]. For the fourth quarter of 2024, total revenues increased by 11% to $9.1 billion compared to the same period in 2023 [amgen.com/newsroom/press-releases/2025/02/amgen-reports-fourth-quarter-and-full-year-2024-financial-results].

Looking back, Amgen also reported strong financial results in previous years. In 2023, total revenues were $28.19 billion, and in 2022, revenues reached $26.3 billion, a 1% increase from the prior year [investors.amgen.com/stock/fundamentals/income-statement]. The company's consistent growth underscores its position as one of the world's leading biotechnology companies [investors.amgen.com/].

Amgen maintains a strong financial outlook, with anticipated net sales of $36.75 billion for the year ending December 2025 [investors.amgen.com/stock/fundamentals/income-statement]. The company actively engages with the investment community, hosting events such as the Goldman Sachs 47th Annual Global Healthcare Conference and the Jefferies Global Healthcare Conference [investors.amgen.com/].

Amgen also demonstrates its commitment to shareholders by consistently increasing its dividend per share, marking its 13th consecutive increase in 2024 [amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/investors/2024-annual-report-letter-and-10k.pdf].

Amgen (amgen.com) actively participates in numerous industry events, frequently presenting at significant healthcare conferences. The company's Events Calendar on its investor relations page lists upcoming and past participations, which often include major financial and healthcare conferences [investors.amgen.com/news-and-events/events-calendar/]. For instance, Amgen has presented at the Goldman Sachs 47th Annual Global Healthcare Conference, the Jefferies Global Healthcare Conference, and the Bank of America Merrill Lynch Global Healthcare Conference in June 2026 [investors.amgen.com/news-and-events/events-calendar/].

Beyond these, Amgen consistently engages with the investment community through events such as the 44th Annual J.P. Morgan Healthcare Conference [investors.amgen.com/events/event-details/44th-annual-jp-morgan-healthcare-conference], the 46th Annual TD Cowen Health Care Conference [investors.amgen.com/events/event-details/46th-annual-td-cowen-health-care-conference], and the 2025 Wells Fargo Healthcare Conference [investors.amgen.com/events/event-details/2025-wells-fargo-healthcare-conference]. The company also hosts regular earnings conference calls, such as the Amgen Q1 2026 Earnings Conference Call, to discuss its financial results [investors.amgen.com/events/event-details/44th-annual-jp-morgan-healthcare-conference].

Amgen also ensures a presence at key scientific and healthcare industry gatherings, with executives like Peter Griffith and Jay Bradner presenting at events such as the Leerink Partners 2026 Global Healthcare Conference [www.amgen.com/newsroom/press-releases/2026/03/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference] and the 8th Annual Evercore ISI HealthCONx Conference [www.amgen.com/newsroom/press-releases/2025/11/amgen-to-present-at-the-8th-annual-evercore-isi-healthconx-conference]. Furthermore, the company has a Scientific Conferences Program designed to educate participants on scientific discoveries and foster interaction within the academic and industry ecosystems, organizing one to three such conferences annually [www-ext.amgen.com/science/scientific-community-initiatives/scientific-conferences-program].

In addition to investor and scientific events, Amgen also holds hiring events to attract top talent as it expands globally, inviting potential candidates to learn more about career opportunities within the company [careers.amgen.com/en/Events].